Friday - May 2, 2025
CHARLOTTE, N.C., Feb. 23, 2023 /PRNewswire/ -- MedSource Labs (Chanhassen, MN) has been awarded a group purchasing agreement for Peripheral Intravenous Catheters (PIVC) Solutions with Premier's AscenDrive™ program, which is designed to drive the highest-level commitment and savings for members through aggregated purchasing of high-quality products and services.
The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the ClearSafe® and TrueSafe® families of products. The AscenDrive™ program brings together Premier's most committed members to coordinate purchasing decisions and maintain standardization across their facilities. By providing additional value to Premier contracted suppliers through volume and commitment, the program is expected to achieve best-in-market pricing.
"We are thrilled to have been awarded this agreement, which can allow Premier members to secure enhanced savings and exclusive benefits on high-quality peripheral IV catheters," said Todd Fagley, Founder of MedSource Labs. "We know through this collaboration MedSource will help to shape the future of safety catheters in the U.S. and beyond."
PERIPHERAL IV CATHETER MARKET
At an estimated annual spend of over $5 billion in the US alone, Peripheral Intravenous Catheter insertion (PIVC) is a routine hospital procedure used during the administration of intravenous drugs, blood products and parenteral medication. 98% of all acute care admissions will receive at least one peripheral IV catheter on admission.
Premier, Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.
ABOUT MEDSOURCE LABS
Celebrating 20 years as a trusted provider of quality medical products, MedSource Labs specializes in customized, Class II product development, manufacturing and commercialization using our comprehensive EMERGE process—transforming good ideas into market-ready medical devices.
Last Trade: | US$20.41 |
Daily Change: | 0.06 0.29 |
Daily Volume: | 703,086 |
Market Cap: | US$1.960B |
February 04, 2025 December 03, 2024 November 05, 2024 August 19, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load